12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

QVA149: Additional Phase III data

Additional data from the double-blind, international Phase III SPARK trial in 2,224 patients with severe to very severe COPD showed that once-daily QVA149 significantly reduced the rate of moderate to severe COPD exacerbations from baseline to week 64, the primary endpoint, by 12% vs. once-daily 50 µg NVA237 (0.84 vs. 0.88 annual rate of exacerbations, p=0.038). QVA149 also significantly reduced the rate of all COPD exacerbations by 15% vs. NVA237 (p=0.0012) and by 14% vs. open-label 18 µg tiotropium (p=0.0017). Additionally, QVA149 significantly increased trough forced expiratory...

Read the full 415 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >